Written by: Kirollos S. Hanna, PharmD, BCPS, BCOP
Download Here

Patients receiving cancer therapies should be adequately assessed and managed to prevent chemotherapy-induced nausea and vomiting (CINV). 5-hydroxytryptamine (5-HT3) receptor antagonists, neurokinin-1 receptor (NK1R) antagonists, glucocorticoids, benzodiazepines, dopaminergic agents and other therapeutic classes have demonstrated substantial antiemetic activity. Despite proven efficacy, choice of therapy should be tailored to the individual patient based on the distinct types of CINV, patient risk factors and emetogenic potential of therapy. Guidelines for antiemetic therapy for intravenously administered chemotherapy according to the estimated risk of CINV are available from American Society of Clinical Oncology, National Comprehensive Cancer Network and the Multinational Association of Supportive Care in Cancer/ European Society for Medical Oncology1-3. Optimal control and prevention of CINV has been associated with improved adherence to cancer therapy stressing the importance of understanding and adhering to these guidelines4,5.
Continue reading Chemotherapy-Induced Nausea and Vomiting

Read More

Written by: Natasha Heimbigner, PharmD
Download Here

The use of immunotherapy in cancer treatment has been expanding over the last several years. The most common adverse effect with these medications are dermatologic toxicities, gastrointestinal, hepatic, and endocrine toxicities. Management of immunotherapy related rash is an important intervention for the patient’s quality of life and buy in to continuation of therapy. Continue reading Managing Immunotherapy Treatment Related Rash

Read More

Written by: Michelle Phillips, PharmD
Download Here

Summary of dosing, administration, and clinical experience to ease the dispensing and management of niraparib.
Continue reading Niraparib dose adjustment based on weight and platelet counts

Read More

Written by: Jody Agena, PharmD
Download Here

Understand how to effectively manage adverse effects of Regorafenib treatment in Hepatocellular Carcinoma.
Continue reading Regorafenib in the treatment of Hepatocellular Carcinoma

Read More